Skip to main content
. 2021 Mar 11;10(3):617. doi: 10.3390/cells10030617

Figure 4.

Figure 4

Effects of pharmacological PLK2 inhibition in human pulmonary MRC5 fibroblasts. (a) Quantification and representative immunofluorescence images of αSMA myofilaments in MRC5 fibroblasts under control conditions and in the presence of 100 nM or 1 µM specific PLK2 inhibitor (TC-S 7005) (n = 8 per group). The nuclei were stained with DAPI (blue). The scale bars equal 50 µm. (b) Quantification and representative immunofluorescence images of extracellular collagen 1 (Col1) deposition in MRC5 fibroblasts under control conditions and in the presence of 100 nM or 1 µM specific PLK2 inhibitor (TC-S 7005) (8 ≤ n ≤ 10). (c) Representative images of TUNEL staining to detect apoptosis. (d) Proliferation curves of MRC5 fibroblasts under control conditions and in the presence of 100 nM or 1 µM specific PLK2 inhibitor (TC-S 7005) (n = 4 per group). Cells were counted after 3 and 6 days. (e–g) Quantification of ACTA2, COL1A1 and COL3A1 gene expression determined by RT qPCR in MRC5 fibroblasts under control conditions and in the presence of 100 nM or 1 µM specific PLK2 inhibitor (TC-S 7005) (6 ≤ n ≤ 8). * p < 0.05. ** p < 0.01. *** p < 0.001. n.s. = not significant.